Pyrimidinylpiperazine

From Self-sufficiency
Revision as of 11:43, 14 April 2010 by El3ctr0nika (Talk)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Pyrimidinylpiperazine
File:Pyrimidinylpiperazine.png
style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers
PubChem 88747
ChemSpider 80080
SMILES Script error: No such module "collapsible list".
InChI Script error: No such module "collapsible list".
style="background: #F8EABA; text-align: center;" colspan="2" | Properties
Molecular formula C8H12N4
Molar mass 164.21 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

1-(2-Pyrimidinyl)piperazine (1-PP, 1-PmP) is a chemical compound and piperazine derivative. It is known to act as an α2-adrenergic receptor antagonist,[1] and as a 5-HT1A receptor partial agonist to a much lesser extent.[2] It does not appear to have any significant affinity for the D2 or α1-adrenergic receptors.

A number of pyrimidinylpiperazine derivatives are drugs, including:

The anxiolytics are also classified as azapirones due to the azaspirodecanedione moiety in their structures. 1-PP is a common metabolite of most or all of the listed agents.[1][3] Alnespirone, binospirone, and enilospirone, despite being azapirones, are not piperazines and therefore do not metabolize to 1-PP, and while perospirone and tiospirone are piperazines, they are instead benzothiazole-substituted piperazines and do not metabolize to 1-PP either.

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



  1. 1.0 1.1 Blier; Curet, O; Chaput, Y; De Montigny, C (1991). "Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission". Neuropharmacology. 30 (7): 691–701. doi:10.1016/0028-3908(91)90176-C. PMID 1681447.  edit
  2. Zuideveld, K. P.; Rusic-pavletic, J.; Maas, H. J.; Peletier, L. A.; Van Der Graaf, P. H.; Danhof, M. (2002). "Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats". The Journal of pharmacology and experimental therapeutics. 303 (3): 1130–1137. doi:10.1124/jpet.102.036798. PMID 12438536.  More than one of |author2= and |last2= specified (help); More than one of |author3= and |last3= specified (help); More than one of |author4= and |last4= specified (help); More than one of |author5= and |last5= specified (help); More than one of |author6= and |last6= specified (help) edit
  3. Astier; Lambás Señas, L; Soulière, F; Schmitt, P; Urbain, N; Rentero, N; Bert, L; Denoroy, L; Renaud, B (2003). "In vivo comparison of two 5-HT1A receptors agonists alnespirone (S-20499) and buspirone on locus coeruleus neuronal activity". European journal of pharmacology. 459 (1): 17–26. doi:10.1016/S0014-2999(02)02814-5. PMID 12505530.  edit